Who are Folinic Acid, interferon-alpha's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): LM-108 in combination with Toripalimab, Miltefosine plus GM-CSF.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/folinic-acid-interferon-alpha.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Folinic Acid, interferon-alpha — Competitive Intelligence Brief

Folinic Acid, interferon-alpha (Folinic Acid, interferon-alpha) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunotherapy combination. Area: Oncology.

phase 3 Immunotherapy combination Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Folinic Acid, interferon-alpha (Folinic Acid, interferon-alpha) — University of Ulm. This combination uses folinic acid to enhance interferon-alpha's immunostimulatory effects, potentially improving anti-tumor immune response.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Folinic Acid, interferon-alpha TARGET	Folinic Acid, interferon-alpha	University of Ulm	phase 3	Immunotherapy combination
LM-108 in combination with Toripalimab	LM-108 in combination with Toripalimab	LaNova Medicines Limited	phase 3	Immunotherapy combination (checkpoint inhibitor + unknown immunomodulator)	PD-1 (Toripalimab); LM-108 target unknown
Miltefosine plus GM-CSF	Miltefosine plus GM-CSF	Hospital Universitário Professor Edgard Santos	phase 3	Antiparasitic immunotherapy combination	Leishmania cell membrane; GM-CSF receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunotherapy combination class)

University of Ulm · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Folinic Acid, interferon-alpha — Competitive Intelligence Brief. https://druglandscape.com/ci/folinic-acid-interferon-alpha. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab